Monadia (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells of the nasal mucosa. This binding alters gene transcription, leading to decreased production of inflammatory cytokines and chemokines, and suppresses immune cell activation. The result is reduced swelling, mucus production, and overall inflammation within the nasal passages.

The specific dose and frequency of Monadia are determined by the prescribing clinician based on the patient’s age, severity of symptoms, and clinical response. Typically, a few sprays per nostril once daily are used, but the exact regimen should follow the healthcare provider’s instructions and the product labeling.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To request Monadia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Monadia’s active ingredient, mometasone furoate, is a high‑potency intranasal corticosteroid with a favorable safety profile when used at recommended doses. Compared with older agents such as fluticasone or budesonide, mometasone offers similar or greater anti‑inflammatory efficacy with a low incidence of systemic absorption, making it a preferred option for many clinicians.

Monadia should be stored at room temperature, below 25 °C (77 °F). Keep the spray bottle in its original packaging, protect it from excessive heat, moisture and direct sunlight. Do not freeze the product. If the canister has been opened for longer than the recommended period, discard it according to local regulations.

Monadia is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, and insert the nozzle into one nostril while closing the other nostril with a finger. Press the actuator to deliver the prescribed number of sprays, then repeat in the opposite nostril if directed. Avoid blowing the nose immediately after dosing.

Although uncommon, serious adverse events can occur with intranasal corticosteroids. These include adrenal suppression, cataracts, glaucoma, severe allergic reactions such as anaphylaxis, and nasal septum perforation. Patients should seek immediate medical attention if they experience visual disturbances, persistent nosebleeds, severe headache, or signs of systemic steroid effects.

Monadia is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active untreated nasal infections, recent nasal surgery, or severe nasal trauma. Children under the age specified in the product labeling should not use the spray unless directed by a qualified healthcare professional.